ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1243

Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis

Cécile Gaujoux-Viala1, Laure Gossec2, Christel Castelli3, Cédric Lukas4, Françoise Barchechath-Flaisler5, Jean-Pierre Daures6 and Maxime Dougados7, 1Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, 2Paris 06 University and AP-HP, Hôpital Pitié Salpêtrière, Paris, France, 3BESPIM, Nîmes University Hospital and EA2415, Nîmes, France, 4Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 5Nîmes University Hospital, Rheumatology Department, Nimes, France, 6EA2415, Nîmes, France, 7Paris Descartes University, Paris, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Economics, health care cost and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Health Services Research - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  The quantification of health improvements is essential, notably in the current context of increasingly expensive therapies and more and more limited resources. Preference-based measures of health have become important for estimating health states in calculating quality-adjusted life years (QALYs), an essential component of cost-utility analysis. The SF-6D is an indirect preference-based health-related quality of life instruments increasingly being used for economic evaluation of clinical interventions and health programs. Data on economic as well as QoL outcomes among early axial Spondyloarthtritis (axSpA) patients remain scarce. Objectives: To evaluate the validity of an utility measure, the SF-6D, in early axSpA especially concerning the ability of this measure to reflect the change in patients’ condition over time.

Methods:  DESIR (Devenir des Spondyloarthropathies Indifférenciées Récentes) is a French, multicentre, longitudinal cohort of 708 patients with early inflammatory back pain suggestive of axSpA. SF-6D utility measures were assessed in 607 patients over 1 year. To investigate whether the change in SF-6D is a valid measure of change in axSpA health status, we used Spearman’s product-moment correlation to compare change scores for SF6D with those for external measures of health, the HAQ, SF36 physical component, SF36 mental component and AS-QOL from baseline to 6 and 12 months. Responsiveness was tested by the effect size (ES) at 6 and 12 months for the entire sample and subgroups by disease evolution (increase or decrease-stabilization in BASDAI). Bootstrap methods were used to estimate 95% confidence intervals [95% CI]. Sensitivity to change of the HAQ was calculated as a benchmark.

Results: At baseline, mean value of SF-6D was 0.69±0.12 (range 0.30 to 0.95). The distribution was near normal. Few missing values were observed: 2.4%. No floor or ceiling effects were evidenced. Correlations of the SF6D change with change in HAQ and physical component of SF-36 scores were moderate at 6 months (r=-0.42 and 0.44, respectively). Correlations with change in mental component of SF-36 and AS-QOL scores were good (r=0.60 and -0.60, respectively). Correlations were stable over 1 year. For the entire sample at 6 months, the SF-6D was more sensitive to change than the HAQ: ES 0.36 [95% CI 0.28;0.44] versus -0.22 [-0.28;-0.17]. The SF-6D was more responsive than the HAQ for improved condition: ES 0.45 [0.37;0.54] vs -0.32 [-0.38;-0.26] without difference for patients with deteriorated condition: ES SF-6D -0.23 [-0.41;-0.04] vs 0.33 [0.18;0.50] for HAQ. Results were similar at 12 months.

Conclusion:  The SF-6D is valid and able to reflect the change in patients’ condition over time, especially improvement, in patients with early inflammatory back pain suggestive of axSpA.


Disclosure: C. Gaujoux-Viala, None; L. Gossec, None; C. Castelli, None; C. Lukas, None; F. Barchechath-Flaisler, None; J. P. Daures, None; M. Dougados, None.

To cite this abstract in AMA style:

Gaujoux-Viala C, Gossec L, Castelli C, Lukas C, Barchechath-Flaisler F, Daures JP, Dougados M. Validity of the Short Form 6D Utility Measure in Early Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validity-of-the-short-form-6d-utility-measure-in-early-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-of-the-short-form-6d-utility-measure-in-early-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology